ST未名: 《证券投资与衍生品交易管理制度 》（2025年7月）

Core Points - The document outlines the securities investment and derivative trading management system of Shandong Weiming Biological Pharmaceutical Co., Ltd, aiming to standardize practices, enhance risk control, and protect investor rights [1][2][3] Group 1: General Principles - Securities investment includes new stock subscriptions, stock repurchases, equity investments, bond investments, and other recognized investment behaviors [1] - Derivative trading refers to transactions involving forwards, futures, swaps, options, and other financial instruments based on various underlying assets [2] - The company must adhere to national laws and regulations, assess risks, and ensure that investment activities do not disrupt normal business operations [3][4] Group 2: Approval Authority - The approval authority for securities investments is defined based on the percentage of the company's audited net assets, with specific thresholds for board and shareholder approval [4][5] - Derivative trading requires a feasibility analysis report to be submitted to the board for approval, with certain transactions needing shareholder approval if they exceed specified financial thresholds [5][6] Group 3: Management Structure - The board of directors and the shareholders' meeting serve as decision-making bodies for securities investments and derivative trading [6][7] - The investment review team is responsible for project investigation, analysis, and preliminary evaluation, while the financial center manages funds and financial aspects of the projects [7][8] Group 4: Risk Control Measures - The company implements an authorization system for trading operations, requiring prior review and approval of investment projects [8][9] - Regular audits and risk assessments are conducted to ensure compliance with internal control measures and to monitor the performance of investment activities [9][10] Group 5: Information Disclosure - The company is obligated to disclose information regarding securities investments and derivative trading in accordance with relevant regulations, including timely submission of board resolutions and feasibility reports [11][12] - Any significant losses or changes in investment status must be reported immediately to ensure transparency and compliance [12][13]